Ophthalmic Goods Manufacturing (U.S.) — NAICS 339115

An investor's primer. Plain language, dual-audience: relevant to both public-market and private investors.

1. Overview

Ophthalmic goods manufacturing is the business of making the things people put in front of, or on, their eyes to see better: prescription eyeglass lenses, eyeglass frames, contact lenses, sunglasses, standard-power reading glasses, and protective eyewear. It is a hybrid of consumer branding and regulated medical-device manufacturing — Ray-Ban is a fashion label, but a box of daily contact lenses is an FDA-cleared medical device.

Why an investor cares: demand is unusually durable. The Vision Council estimates that 94% of U.S. adults — roughly 250 million people — regularly use some form of eyewear.[16] The CDC reports 45 million Americans wear contact lenses.[19] Roughly 128 million U.S. adults have age-related "reading glasses" vision loss (presbyopia), and childhood nearsightedness (myopia) is climbing.[17][20] People need to see whether or not the economy is booming, which makes the core business defensive. Contact lenses in particular behave like a razor-and-blades consumable: a wearer buys a fresh supply every year, for decades.

Public vs. private ways in. There is no clean "pure play" — the largest makers are diversified eye-health companies (The Cooper Companies, Bausch + Lomb, Alcon) or a foreign-listed giant (EssilorLuxottica). Much of the value chain — optical stores, optometry practices, small frame and specialty-lens makers — is privately held. Both routes are covered below.

2. What it is, and how it's structured

In scope (NAICS 2022 code 339115). The federal definition covers establishments primarily engaged in making ophthalmic goods: prescription eyeglasses (except when ground in a retail store), contact lenses, sunglasses, eyeglass frames and parts, standard-power reading glasses, and protective/safety eyewear. It also includes non-retail lens grinding, polishing and coating.[4]

What it explicitly excludes — and where those activities are counted instead. This matters, because several things people think of as "eye stuff" are classified elsewhere and are therefore not in this industry's federal numbers:[4]

The practical takeaway: the surgical and IOL businesses of Alcon and Bausch + Lomb — some of the highest-margin "ophthalmic" revenue there is — sit in adjacent codes, not in 339115.

Three distinct production systems. There are three economically different activities inside this code. Contact lenses are regulated, high-volume medical-device manufacturing: polymers or silicone-hydrogel materials are molded or lathed, hydrated, inspected, packaged and sterilized — scale, process yield, and validated quality systems are critical.[12] Prescription spectacle lenses are more of a distributed, made-to-order laboratory business: a lab receives a prescription and frame specification, digitally surfaces and polishes a semi-finished lens, applies coatings, edges the lens and mounts it — turnaround time, remakes, and logistics matter as much as raw material cost. Frames, sunglasses, readers and safety eyewear resemble branded consumer-products manufacturing: acetate, injected plastic, or metal components are formed and assembled, often through international contract manufacturers — brand licensing, design, and retail distribution can capture more value than physical fabrication.[15]

Ownership mix. The industry is a barbell. At one end, a handful of very large, often foreign-headquartered multinationals (EssilorLuxottica, Alcon, Bausch + Lomb, plus Johnson & Johnson's contact-lens arm) dominate volume. At the other, a long tail of small U.S. firms — custom rigid gas-permeable and scleral lens labs, safety-eyewear makers, niche and independent frame designers — serve specialty niches. The four largest firms account for 59.3% of industry receipts, and the top eight for 73.3%, so concentration is high.[2] Several important competitors are unavailable to public investors, including VSP's not-for-profit integrated system and foundation-owned Carl Zeiss.[21][22]

3. How big it is (federal figures)

The core federal statistics for U.S. ophthalmic goods manufacturing:

The market-concentration index (HHI) is suppressed in the federal data, so we do not state one.[2]

The undercount caveat — read this before quoting "$6.5 billion." That figure is U.S. factory shipments, and it dramatically understates the size of the American eyewear economy for three reasons. First, most frames and many finished lenses sold in the U.S. are imported, not domestically manufactured — China alone is the largest source — so consumption far exceeds domestic production.[11] Second, the bulk of the retail dollar lands in other NAICS codes: The Vision Council valued the broad 2025 U.S. optical ecosystem at $69.5 billion, though that includes eye exams, retail sales, contact lenses, prescription lenses, frames, readers and sunglasses — a downstream expenditure measure, not manufacturing output.[16] Third, IOLs and surgical devices — a multi-billion-dollar slice of "ophthalmic" business — are classified outside 339115.[4][7] So this is a real, well-measured manufacturing industry, but it is a thin slice of the money spent on eyes.

4. The investable universe

There is no U.S.-listed pure play on 339115. The closest, and the diversified companies whose eyewear/contact-lens divisions dominate the category:

Retail-end proxies (not manufacturers). For investors who want eyewear exposure through the store rather than the factory: Warby Parker (NYSE: WRBY, ~$872M 2025 revenue, 54.0% gross margin but only $1.6M net income) and National Vision (NASDAQ: EYE, ~$1.82B 2024 revenue) — both are optical retailers (NAICS 456130), though Warby Parker designs its own frames.[15] The Vision Council found that more than 80% of frames and lenses are still purchased in physical locations, while contact lenses have the greatest online penetration.[16]

Major private / other owners. Much of the industry is not on public markets: Carl Zeiss (lenses; wholly owned by the Carl Zeiss Foundation)[22], HOYA (Japan-listed lenses; MiyoSmart), Safilo / Marcolin / De Rigo (frames), and VSP Vision (a U.S. not-for-profit eye-health company that owns Marchon frames, Visionworks stores, and the EyeMed-rival VSP insurance plan).[21] The small-U.S.-maker tail is almost entirely private or family-owned.

5. How the money works

Owners in this industry make money on units × price × gross margin, with several specific levers:

• Recurring consumables (the best economics). Contact lenses are a razor-and-blades model: a wearer re-orders indefinitely, and the industry has pushed buyers toward daily disposables (one pair per day = ~30× the units of a monthly lens). In fiscal 2025, CooperVision generated $2.74B of sales and $730M of segment operating income — a derived operating margin of about 26.6% — while spending $323M on capital expenditure (~11.8% of segment sales). Corporate costs are not allocated to the segment, so this overstates the margin available to a stand-alone shareholder, but demonstrates the economics of a scaled global contact-lens franchise.[12]
• Mix and premiumization — the main margin dial. A basic clear single-vision lens is near-commodity; the money is in upgrades: toric lenses (for astigmatism), multifocal lenses (for presbyopia), silicone-hydrogel dailies, anti-glare/blue-light coatings, progressive spectacle lenses, and myopia-control products. Each carries a higher average selling price and margin. "Mix shift to specialty" is the phrase to watch in results.[12]
• Capacity utilization and scale. Contact-lens and lens plants are highly automated and capital-intensive (hundreds of millions of dollars each). Fixed-cost leverage means volume and utilization drive margins — the classic manufacturing dynamic. This is a barrier that keeps the industry concentrated. Cooper explicitly warns that margin preservation depends on scaling capacity and obtaining materials at reasonable cost.[12]
• Brand and IP pricing power. In frames and sunglasses, the markup is fashion-driven — Ray-Ban and Oakley, plus licensed designer names, command premium prices. In lenses and contacts, patents on materials and optical designs protect margins and slow commoditization.[8]
• Replacement cycle. Eyeglasses are replaced roughly every couple of years (prescription drift plus fashion); sunglasses more discretionary. Repeat demand plus an aging population underpins volume.

Cost and cyclicality. Key costs are R&D and FDA clearance (lenses are medical devices), polymers/silicone raw materials (some from sole or limited suppliers), tariffs on imported components, and marketing/SG&A.[12] The core vision-correction business is defensive; the premium, fashion, and sunglasses end is discretionary — in downturns consumers stretch replacement cycles and trade down, so the high-margin upgrade mix is the part that softens. The Vision Council found that U.S. optical-product volumes and eye exams declined during 2025 even as higher prices lifted market value.[16]

6. What drives demand

• Aging. ~128 million U.S. adults have presbyopia (the near-vision loss that starts in the 40s); the 65+ population keeps growing — Census projections indicate that by 2030 one in five Americans will be of retirement age.[20][23] An older National Eye Institute projection estimated that U.S. visual impairment or blindness could exceed 8 million cases by 2050, with another 16.4 million people experiencing correctable refractive difficulty.[24] Older eyes mean more lenses, stronger prescriptions, and eventually cataract surgery.
• The myopia epidemic. Nearsightedness is rising, especially in children (more screen time, less time outdoors). Roughly 40%+ of the U.S. population is myopic. This spawned the fastest-growing niche — myopia management (CooperVision's MiSight contact lens, and spectacle lenses like Essilor's Stellest, FDA-authorized in 2025, and HOYA's MiyoSmart).[17]
• Screens / digital eye strain, driving demand for blue-light and computer-optimized premium lenses.[16]
• Vision insurance (VSP, EyeMed) that funds routine exams and a new pair every year or two, lifting purchase frequency. Note: traditional Medicare generally covers only one pair of eyeglasses or contact lenses after cataract surgery involving an intraocular lens and does not cover routine replacement eyewear — much of the market therefore remains employer-plan, Medicare Advantage or out-of-pocket spending.[25]
• Fashion and brand cycles for frames and sunglasses — and a new adjacency, smart eyewear (e.g., Ray-Ban Meta), opening a growth category on top of vision correction.[8]

7. Regulation

• FDA (medical devices). Contact lenses — including purely cosmetic colored/plano lenses — are regulated devices. Daily-wear and disposable contact lenses are generally Class II devices; extended-wear and overnight orthokeratology lenses can be Class III.[26] Most soft and rigid gas-permeable lenses clear via a 510(k) (demonstrating equivalence to an existing lens); novel or therapeutic lenses need full Premarket Approval (PMA) with clinical data. Makers must register, list products, and manufacture under FDA quality-system rules.[9] Even ordinary spectacles and sunglasses are FDA-regulated: they are generally exempt from premarket notification, but manufacturers and importers remain subject to establishment registration, device listing, quality-system, labeling and impact-resistance requirements — and imports can be detained for noncompliance.[27]
• FTC selling rules. The Fairness to Contact Lens Consumers Act (2004) and the FTC Contact Lens Rule govern how lenses are sold: prescribers must release the prescription, prescriptions are valid at least one year (absent a documented medical reason), and a seller filling an order must verify it — the prescriber has 8 business hours to respond or the prescription auto-verifies. These rules enabled online and third-party sellers and limit manufacturers' ability to tie the exam to product sale.[10]
• Safety standards. Protective eyewear must meet ANSI Z87.1; OSHA mandates it in many workplaces where workers face particle, chemical or radiation hazards, and prescription wearers must be accommodated. Standards create durable demand but also product-liability exposure if performance claims fail.[28]
• Trade / tariffs (a live cost issue). The U.S. imports most frames and many lenses. In 2025, Chinese-origin frames, sunglasses, and readers faced combined tariff rates around 150%+, with additional reciprocal tariffs of ~15–20% on the EU, Japan, and Vietnam — a direct hit to input costs that the industry's trade group (The Vision Council) has flagged as material.[11] Warby Parker's 2025 margin disclosure provides direct evidence that tariff costs can reach reported gross margin.[15]

8. Competitive dynamics & consolidation

The industry is one of the more consolidated in consumer/medical products.

• Contact lenses are a global oligopoly — the "Big Four" of Johnson & Johnson (Acuvue), Alcon, CooperVision, and Bausch + Lomb hold the overwhelming majority of the world market, and the U.S. mirrors that. High capital intensity, FDA barriers, patents, and distribution control keep new entrants out. CooperVision describes competition as depending on product quality, differentiated materials, efficient manufacturing and the ability to make high-, medium- and low-volume lenses across many parameters.[5][12]
• EssilorLuxottica is a vertically integrated colossus, formed by the 2018 merger of lens-maker Essilor and frame/retail-maker Luxottica. It spans lenses, frames, sunglasses, retail chains (LensCrafters, Sunglass Hut, Target Optical), and vision insurance (EyeMed) — and keeps acquiring.[8]
• Vertical integration blurs the lines between "manufacturer" and "retailer": EssilorLuxottica and VSP Vision both own factories and store chains, which shapes pricing and shelf access for everyone else. Warby Parker identifies EssilorLuxottica and not-for-profit VSP as large integrated competitors owning brands, retail banners, insurance relationships and optical-laboratory networks.[15]
• Recent M&A signals. Alcon agreed to buy STAAR Surgical in 2025, but shareholders rejected the deal and it was terminated in January 2026 — a reminder that the surgical/IOL adjacency is an active battleground.[18] Bausch + Lomb's future ownership (its relationship to former parent Bausch Health) remains an open question. At the retail/DTC end, Warby Parker continues to pressure legacy incumbents.
• The federal concentration data confirm it: CR4 of 59.3% and CR8 of 73.3% in domestic manufacturing.[2]

9. Risks

• Tariffs and supply chain. Heavy reliance on imported frames and components (especially China) makes margins hostage to trade policy; 2025 tariff increases are a real cost shock.[11] Cooper identifies chemicals, packaging and components as major inputs and reports that some silicone-hydrogel materials come from sole or limited suppliers — supply disruption can cause shortages, production interruption or costly requalification.[12]
• Foreign-exchange and geographic risk. The leaders earn revenue globally and several are foreign-domiciled, so reported results swing with the dollar.
• Regulatory / recall risk. As device makers, companies face FDA quality enforcement, contamination or defect recalls, and clinical-trial risk for new lenses. Manufacturing changes can require new review, and inspection failures can produce warning letters, import holds, recalls, seizures or plant disruption.[9]
• Discretionary softness. The premium-lens, designer-frame, and sunglasses mix — the profitable part — is cyclical; recessions compress it.
• Pricing and disruption. Online price transparency, private label, and direct-to-consumer brands pressure frame and lens pricing.
• Technology substitution (double-edged). Refractive surgery (LASIK), IOLs, and emerging pharmaceuticals (atropine for kids, presbyopia eye drops) could erode lens demand over the long run — while the myopia epidemic simultaneously expands it. Surgery is not a complete substitute because many patients remain ineligible, still require readers or retain eyewear as backup. Net direction is a forward-looking judgment, not a settled fact.
• Concentration/antitrust scrutiny. The dominant vertically integrated player invites regulatory attention in multiple jurisdictions.

10. How to invest, and the outlook

Public-market routes.

• Closest to a pure play: The Cooper Companies (COO) — CooperVision is contact-lens-centric and squarely in this industry, though CooperSurgical remains a material second business.[12]
• Diversified eye-health: Bausch + Lomb (BLCO) (contacts + consumer eye health + surgical/pharma; a turnaround/separation story) and Alcon (ALC) (a big contact-lens/ocular-health arm, but the bulk of its value is surgical/IOL, an adjacent code).[13][14]
• The eyewear giant: EssilorLuxottica via ADR (ESLOY) or Paris listing (EL) — the way to own lenses + frames + retail + smart eyewear in one name.[8]
• Incidental exposure: Johnson & Johnson (JNJ) owns Acuvue but it is immaterial to the stock.
• Retail-end proxies: Warby Parker (WRBY) and National Vision (EYE) for the store side rather than the factory.[15]
• Note: there is no dedicated U.S. eyewear ETF; broad exposure otherwise comes bundled inside medical-device and health-care funds.

Private-market routes. The private side is large: private-equity ownership of frame makers, specialty and rigid-gas-permeable lens labs, safety-eyewear firms, and contract manufacturers; foundation/family ownership (Zeiss); nonprofit ownership (VSP Vision); and venture-backed direct-to-consumer eyewear brands. Roll-ups of independent optical labs and specialty-lens shops are a recurring PE thesis. The attractive acquisition cases are typically laboratories with dense regional routes, high service levels, low remake rates and sticky optometrist relationships. Principal diligence hazards are customer concentration, old surfacing or coating equipment, underfunded quality systems, tariff-dependent sourcing and confusion between high retail gross margin and the materially lower cash economics of the manufacturing operation.

Outlook (forward-looking judgment). The demand backdrop is structurally favorable: an aging population, a spreading myopia epidemic, near-universal corrective-lens use, and premiumization all push the core market higher over time, and myopia management plus smart eyewear are genuine new growth engines.[16][17] The near-term tension is between that steady volume and margin headwinds — import tariffs, currency, and discretionary softness at the premium/sunglasses end.[11] Consolidation is likely to continue, and the manufacturer-retailer line will keep blurring. For investors, the industry offers defensive, annuity-like consumable economics (contact lenses) alongside cyclical, brand-driven upside (frames and sunglasses) — but almost always packaged inside larger diversified companies rather than a single ophthalmic-goods stock.

---

Sources

1. U.S. Census Bureau. County Business Patterns 2023 (NAICS 339115) — establishments, employment, annual payroll. 2023. https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau. 2022 Economic Census — Concentration of Largest Firms & Statistics of U.S. Businesses (NAICS 339115) — receipts, firm count, CR4/CR8/CR20/CR50 (HHI suppressed). 2022. https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Small Business Administration. Table of Small Business Size Standards (NAICS 339115 = 1,000 employees). 2023. https://www.sba.gov/document/support-table-size-standards
4. U.S. Census Bureau / NAICS 2022. Industry 339115, Ophthalmic Goods Manufacturing — definition and cross-references. 2022. https://www.census.gov/naics/?details=33911&input=339&year=2022
5. Grand View Research. Contact Lenses Market Size & Share, Industry Report. 2025. https://www.grandviewresearch.com/industry-analysis/contact-lenses-market
6. GlobeNewswire / Research and Markets. U.S. Contact Lenses Market Size and Share Analysis 2025–2033. 2025. https://www.globenewswire.com/news-release/2025/03/10/3039922/28124/en/U-S-Contact-Lenses-Market-Size-and-Share-Analysis-2025-2033-Featuring-Bausch-Lomb-Alcon-Carl-Zeiss-Meditec-The-Cooper-Companies-Hoya-Corporation-More.html
7. Polaris Market Research / Yahoo Finance. Intraocular Lens (IOL) Market — North America outlook and premium-IOL growth. 2025. https://www.polarismarketresearch.com/press-releases/intraocular-lens-market
8. EssilorLuxottica. 2025 Annual Report — €28.5B revenue, segment mix, adjusted operating margin. 2025. https://www.essilorluxottica.com/api/getCapContent/?download=false&id=291036
9. U.S. Food and Drug Administration. Contact Lenses — medical-device classification and clearance. 2024. https://www.fda.gov/medical-devices/consumer-products/contact-lenses
10. U.S. Federal Trade Commission. Fairness to Contact Lens Consumers Act & Contact Lens Rule — prescription release and 8-business-hour verification. https://www.ftc.gov/business-guidance/resources/contact-lens-rule-guide-prescribers-sellers
11. The Vision Council; Healio. Tariff updates impacting the optical industry; optical products from China tariffed as high as ~155–178%. 2025. https://thevisioncouncil.org/blog/vision-council-provides-latest-updates-tariffs-impacting-optical-industry
12. CooperCompanies. Form 10-K FY2025 — CooperVision revenue, segment operating income, capital expenditure, competitive factors, supply chain risks. 2025. https://www.sec.gov/Archives/edgar/data/711404/000162828025055615/coo-20251031.htm
13. Bausch + Lomb Corporation. Fourth-Quarter and Full-Year 2024/2025 Results — Vision Care segment revenue. 2025. https://www.sec.gov/Archives/edgar/data/1860742/000186074226000006/ex991q4-2025.htm
14. Alcon Inc. (BusinessWire / Nasdaq). Full-Year 2024 Results — $9.8B total; Vision Care ~$4.3B, Surgical ~$5.5B. February 2025. https://www.businesswire.com/news/home/20250222710812/en/Alcon-Reports-Full-Year-2024-Results
15. Warby Parker Inc. Form 10-K FY2025 — $871.9M revenue, 54.0% gross margin, net income, tariff impact, competitive landscape. 2025. https://www.sec.gov/Archives/edgar/data/1504776/000150477626000006/wrby-20251231.htm
16. The Vision Council. U.S. Optical Industry Reaches $69.5 Billion — 94% eyewear usage, channel mix, volume vs. price dynamics. 2025. https://thevisioncouncil.org/blog/us-optical-industry-reaches-695-billion-despite-declines-product-volume-and-eye-exams
17. Healio; Grand View Research. FDA authorizes Essilor Stellest for myopia control (2025); myopia-management market growth; MiSight. 2025. https://www.healio.com/news/optometry/20250926/fda-authorizes-essilor-stellest-spectacle-lenses-for-myopia-control
18. DelveInsight / Yahoo Finance. Alcon–STAAR Surgical merger agreement terminated after shareholder rejection, January 2026. 2026. https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
19. U.S. Centers for Disease Control and Prevention. Contact Lenses — 45 million U.S. wearers. https://www.cdc.gov/contact-lenses/about/index.html
20. IMARC Group; Grand View Research. U.S. Eyewear / U.S. Eye Care Market Size — presbyopia ~128M adults. 2024–2025. https://www.imarcgroup.com/united-states-eyewear-market
21. VSP Vision. Corporate description — not-for-profit eye-health company. https://vspvision.com/purpose.html
22. Carl Zeiss AG. Facts & Figures — wholly owned by the Carl Zeiss Foundation. https://www.zeiss.com/corporate/en/about-zeiss/present/facts-figures/carl-zeiss-foundation.html
23. U.S. Census Bureau. Demographic Projections — one in five Americans of retirement age by 2030. 2020. https://www.census.gov/library/publications/2020/demo/p25-1144.html
24. National Eye Institute. Visual Impairment and Blindness Cases in U.S. Expected to Double by 2050. https://www.nei.nih.gov/about/news-and-events/news/visual-impairment-blindness-cases-us-expected-double-2050
25. U.S. Centers for Medicare & Medicaid Services. Refractive Lens Policy — Medicare coverage limitations for eyewear. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52499&ver=23
26. U.S. Food and Drug Administration. Recognized Contact Lens Standards and Classifications. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=38809
27. U.S. Food and Drug Administration. Sunglasses, Spectacle Frames, Spectacle Lens, and Magnifying Spectacles — registration, listing, and impact-resistance requirements. https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/sunglasses-spectacle-frames-spectacle-lens-and-magnifying-spectacles
28. U.S. Occupational Safety and Health Administration. Eye and Face Protection Standard (1910.133). https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.133